

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CANbridge Pharmaceuticals Inc.**  
**北海康成製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1228)**

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING  
HELD ON AUGUST 3, 2026**

The Board hereby announces that resolution set out in the EGM Notice were duly passed by the Shareholders by way of a poll at the EGM held on Monday, August 3, 2026.

**EXTRAORDINARY GENERAL MEETING (THE “EGM”)**

Reference is made to the circular (the “**EGM Circular**”) and the notice of the EGM (the “**EGM Notice**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) both dated July 15, 2026. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the EGM Circular.

**POLL RESULTS OF EGM**

The Board is pleased to announce that the proposed resolution as set out in the EGM Notice was duly passed by the Shareholders as ordinary resolution by way of poll at the EGM held on Monday, August 3, 2026. The poll results in respect of the resolution passed at the EGM are as follows:

| ORDINARY RESOLUTIONS |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NO. OF VOTES          |           |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------|
|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | For                   | Against   |
| 1.                   | <b>THAT</b> (a) the WuXi Biologics Service Procurement Framework Agreement, the terms thereof and the transactions and the annual caps contemplated thereunder be and are hereby approved, ratified and confirmed; and (b) any one Director be and is hereby authorized for and on behalf of the Company to execute, deliver and/or affix seal on all such other documents, instruments and agreements and to do all such acts or things deemed by him/her to be incidental to, ancillary to or in connection with the matters contemplated in the WuXi Biologics Service Procurement Framework Agreement. | 201,307,108<br>(100%) | 0<br>(0%) |

Please refer to the EGM Notice for the full text of the resolution above.

As more than 50% were cast in favour of the above ordinary resolution, the above ordinary resolution was duly passed as ordinary resolution of the Company.

## GENERAL

As of the date of the EGM, a total of 597,443,347 Shares were in issue. WuXi Biologics, which is indirectly interested in 96,859,693 Shares as at the date of the EGM (representing approximately 16.21% of the issued share capital of the Company as at the date of the EGM), was required under the Listing Rules to abstain, and did abstain, from voting in favour of the resolution proposed at the EGM. Accordingly, the total number of Shares entitling the holders to attend and vote for or against the resolution proposed at the EGM was 500,583,654 Shares.

Save as disclosed above, (i) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolution proposed at the EGM as set out in Rule 13.40 of the Listing Rules, (ii) there was no restriction on any Shareholders to cast votes on the resolution proposed at the EGM, (iii) no Shareholders were required to abstain from voting at the EGM under the Listing Rules, and (iv) none of the Shareholders has stated their intention in the EGM Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking. Five of the seven Directors, namely Dr. James Qun Xue, Ms. Wei Zhao, Mr. Tingwei Wang, Mr. Peng Kuan Chan and Dr. Lan Hu attended the EGM. Dr. Richard James Gregory and Mr. James Arthur Geraghty did not attend the EGM due to other business arrangements.

By Order of the Board  
**CANbridge Pharmaceuticals Inc.**  
**Dr. James Qun Xue**  
*Chairman*

Hong Kong, August 3, 2026

*As of the date of this announcement, the Board comprises Dr. James Qun Xue as an executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.*